AQR Capital Management
PLX icon

AQR Capital Management’s Protalix BioTherapeutics PLX Stock Holding History

AQR Capital Management’s Portfolio PLX Stock Details PLX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$391K Buy
167,826
+137,333
+450% +$291K ﹤0.01% 3500
2026
Q1 		$66.2K Buy
+30,493
New +$75.7K ﹤0.01% 3702
2024
Q3 		– Sell
-57,106
Closed -$66.8K – 2855
2024
Q2 		$66.8K Buy
+57,106
New +$67.5K ﹤0.01% 2526

Other funds holding PLX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
SWP
Stratos Wealth Partners Beachwood, Ohio $9.93B AUM 28.91% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

AQR Capital Management's PLX Position: Q2 2026 in Review

AQR Capital Management increased its Protalix BioTherapeutics (PLX) stake by 450% in Q2 2026, buying an estimated $291K and bringing the position to 167,826 shares worth $391K. The position accounts for ﹤0.01% of the portfolio, ranked #3500.

AQR Capital Management first reported a position in PLX in Q2 2024 and has held it in 3 quarters since. 102 funds tracked by Wall St. Rank hold PLX as of Q2 2026.

  • AQR Capital Management held 167,826 shares of Protalix BioTherapeutics worth $391K as of Q2 2026.
  • AQR Capital Management bought 137,333 Protalix BioTherapeutics shares in Q2 2026, an estimated $291K.
  • Protalix BioTherapeutics made up ﹤0.01% of AQR Capital Management's portfolio in Q2 2026, its #3500 holding.
  • AQR Capital Management first reported a position in Protalix BioTherapeutics in Q2 2024 and has held it in 3 quarters since.
  • 102 funds tracked by Wall St. Rank held Protalix BioTherapeutics as of Q2 2026.

Based on AQR Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.